Skip to main content

Table 6 Descriptive analysis of patients with solicited adverse events, all patients (N = 761)

From: Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study

  All Patients N = 761 OM N = 186 LM N = 152 AM N = 216 OLC N = 47 OAC N = 68 OC N =48 OMS N = 44
Solicited side effects n % n % n % n % n % n % n % n %
Any 662 87.0 157 84.4 135 88.8 185 85.7 45 95.7 61 89.7 44 91.7 35 79.6
Weight increase 530 69.7 144 77.4 99 65.1 140 64.8 42 89.4 49 72.1 30 62.5 26 59.1
Sedation 369 48.5 100 53.8 56 36.8 101 46.8 27 57.5 37 54.4 23 47.9 25 56.8
Cognitive dysfunctions 321 42.2 74 39.8 68 44.7 78 36.1 25 53.2 36 52.9 26 54.2 14 31.8
Sexual dysfunctions 294 38.6 78 41.9 48 31.6 79 36.6 30 63.8 33 48.5 15 31.3 11 25.0
Gastroint. disorders 221 29.0 40 21.5 58 38.2 59 27.3 16 34.0 15 22.1 19 39.6 14 31.8
Dizziness 215 28.3 46 24.7 44 29.0 64 29.6 13 27.7 19 27.9 15 31.3 14 31.8
Tremor 195 25.6 25 13.4 62 40.8 35 16.2 22 46.8 23 33.8 22 45.8 6 13.6
Thirst 169 22.2 30 16.1 58 38.2 36 16.7 18 38.3 12 17.7 10 20.8 5 11.4
Insomnia 165 21.7 41 22.0 33 21.7 46 21.3 12 25.5 12 17.7 14 29.2 7 15.9
Polyuria/nycturia 109 14.3 21 11.3 49 32.2 16 7.4 12 25.5 5 7.4 4 8.3 2 4.6
Menstrual disorders 65 8.5 16 8.6 11 7.2 23 10.7 2 4.3 6 8.8 4 8.3 3 6.8
Thyroid disorders 58 7.6 5 2.7 31 20.4 7 3.2 7 14.9 2 2.9 6 12.5 0 0.0
Akathisia 54 7.1 12 6.5 7 4.6 18 8.3 1 2.1 9 13.2 3 6.3 4 9.1
Parkinson syndrome 21 2.8 3 1.6 5 3.3 6 2.8 1 2.1 3 4.4 2 4.2 1 2.3
Hyperprolactinaemia 18 2.4 3 1.6 5 3.3 3 1.4 3 6.4 3 4.4 0 0.0 1 2.3
Tardive dyskinesia 16 2.1 1 0.5 4 2.6 7 3.2 1 2.1 1 1.5 2 4.2 0 0.0
Dystonia 16 2.1 2 1.1 2 1.3 5 2.3 1 2.1 0 0.0 3 6.3 3 6.8
QTc-Prolongation 8 1.1 0 0.0 3 2.0 3 1.4 0 0.0 1 1.5 1 2.1 0 0.0
  1. Abbreviations: N number of patients, OM Olanzapine monotherapy, LM Lithium monotherapy, AM Anticonvulsive monotherapy, OLC Olanzapine/lithium combination therapy, OAC Olanzapine/anticonvulsive combination therapy, OC Other combinations of mood-stabilizers, OMS Other mood stabilizing therapy.